Covid Vaccine

Breakingviews – Big Pharma’s Vaccine Immunity Will Be Fleeting

LONDON (Reuters Breakingviews) – Big Pharma’s vaccine victory lap may be cut short. The industry’s triumph in dispensing inoculations less than a year after the discovery of the deadly coronavirus has partially vindicated the business models of groups like Pfizer, Moderna and AstraZeneca. But as governments took on much of the risk, pharma groups’ pricing will remain a target after the pandemic.

Riding to the world’s rescue is a welcome corrective for the battered pharmaceutical industry. In recent years the sector has grappled with bribery scandals and accusations of aggressive pricing, exemplified by Mylan’s decision to hike the price of anti-allergy injection EpiPen by 400%.

Read more…